Lars Thomassen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5521761/publications.pdf

Version: 2024-02-01

567281 361022 1,464 63 15 35 citations h-index g-index papers 67 67 67 1921 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurology, The, 2017, 16, 781-788.	10.2	305
2	European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. European Heart Journal, 2019, 40, 3182-3195.	2.2	240
3	Recurrent ischemic stroke: Incidence, predictors, and impact on mortality. Acta Neurologica Scandinavica, 2019, 140, 3-8.	2.1	94
4	Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2,) Tj ETQq0 0 The, 2022, 21, 511-519.	0 rgBT /0 [,] 10.2	verlock 10 T 88
5	Cancer-Associated Stroke: The Bergen NORSTROKE Study. Cerebrovascular Diseases Extra, 2015, 5, 107-113.	1.5	82
6	Prior Cancer in Patients with Ischemic Stroke: The Bergen NORSTROKE Study. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 919-925.	1.6	53
7	NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study). Stroke, 2017, 48, 335-341.	2.0	52
8	When to Screen Ischaemic Stroke Patients for Cancer. Cerebrovascular Diseases, 2018, 45, 42-47.	1.7	47
9	Causes and Predictors for Hospital Readmission after Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2095-2101.	1.6	36
10	Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs, 2015, 29, 811-818.	5.9	31
11	Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. Stroke, 2019, 50, 1279-1281.	2.0	29
12	Hospital Readmission after Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 157-162.	1.6	20
13	Five-year readmission and mortality differ by ischemic stroke subtype. Journal of the Neurological Sciences, 2019, 403, 31-37.	0.6	20
14	Long-Term Effect of Intravenous Thrombolytic Therapy in Acute Stroke: Responder Analysis versus Uniform Analysis of Excellent Outcome. Cerebrovascular Diseases, 2005, 20, 470-474.	1.7	17
15	Thirtyâ€day recurrence after ischemic stroke or TIA. Brain and Behavior, 2018, 8, e01108.	2.2	16
16	A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS). BMC Neurology, 2015, 15, 110.	1.8	15
17	Short-Term Outcome of Spontaneous Intracerebral Hemorrhage in Algarve, Portugal: Retrospective Hospital-Based Study. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 346-351.	1.6	15
18	Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST). International Journal of Stroke, 2019, 14, 508-516.	5.9	15

#	Article	IF	Citations
19	Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. Stroke, 2019, 50, 498-500.	2.0	15
20	A qualitative description of telemedicine for acute stroke care in Norway: technology is not the issue. BMC Health Services Research, 2014, 14, 643.	2.2	14
21	Incidence and case-fatality from spontaneous intracerebral hemorrhage in a southern region of Portugal. Journal of the Neurological Sciences, 2017, 380, 74-78.	0.6	12
22	Bilateral nonâ€traumatic carotid cavernous sinus fistula with spontaneous closure. Acta Ophthalmologica, 1990, 68, 743-747.	1.1	11
23	A stress-related explanation to the increased blood pressure and its course following ischemic stroke. Vascular Health and Risk Management, 2016, Volume 12, 435-442.	2.3	11
24	Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study. International Journal of Stroke, 2017, 12, 998-1004.	5.9	11
25	Tenecteplase versus alteplase after acute ischemic stroke at high age. International Journal of Stroke, 2021, 16, 295-299.	5.9	11
26	Incidence and Etiologies of Stroke Mimics After Incident Stroke or Transient Ischemic Attack. Stroke, 2019, 50, 2937-2940.	2.0	10
27	Short-Term Outcome and In-Hospital Complications After Acute Cerebral Infarcts in Multiple Arterial Territories. Stroke, 2019, 50, 3625-3627.	2.0	10
28	Young ischaemic stroke incidence and demographic characteristics $\hat{a} \in \text{``The Norwegian stroke in the}$ young study $\hat{a} \in \text{``A three-generation research program. European Stroke Journal, 2019, 4, 347-354.}$	5.5	10
29	Atherosclerosis in Trial of Org 10172 in Acute Stroke Treatment Subtypes among Young and Middle-Aged Stroke Patients: The Norwegian Stroke in the Young Study. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 825-830.	1.6	9
30	One-year versus five-year hospital readmission after ischemic stroke and TIA. BMC Neurology, 2019, 19, 15.	1.8	9
31	Clinical outcomes and safety profile of Tenecteplase in wakeâ€up stroke. Acta Neurologica Scandinavica, 2020, 142, 475-479.	2.1	9
32	Visionâ€related quality of life in patients with occipital stroke. Acta Neurologica Scandinavica, 2020, 141, 509-518.	2.1	9
33	Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis. Stroke, 2021, 52, 3786-3795.	2.0	9
34	Thrombolytic Therapy in Acute Ischaemic Stroke. Cerebrovascular Diseases, 2002, 13, 163-167.	1.7	8
35	Prevalence of Intracranial Stenosis in a Norwegian Ischemic Stroke Population. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 1611-1615.	1.6	8
36	Impaired cerebrovascular reactivity may predict delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Journal of the Neurological Sciences, 2019, 407, 116539.	0.6	8

#	Article	IF	CITATIONS
37	Uâ€shaped relationship between hemoglobin level and severity of ischemic stroke. Acta Neurologica Scandinavica, 2019, 140, 56-61.	2.1	8
38	Combined Carotid and Transcranial Ultrasound Findings Compared with Clinical Classification and Stroke Severity in Acute Ischemic Stroke. Cerebrovascular Diseases, 2006, 21, 86-90.	1.7	6
39	Early ischemic CT changes before thrombolysis: The influence of age and diabetes mellitus. Therapeutics and Clinical Risk Management, 2008, Volume 4, 699-703.	2.0	6
40	Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?. Vascular Health and Risk Management, 2014, 10, 49.	2.3	6
41	Stroke patients' knowledge about cardiovascular family history - the Norwegian Stroke in the Young Study (NOR-SYS). BMC Neurology, 2015, 15, 30.	1.8	6
42	Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities. CNS Drugs, 2016, 30, 101-108.	5.9	6
43	Persistent Microembolic Signals in the Cerebral Circulation on Transcranial Doppler after Intravenous Sulfur Hexafluoride Microbubble Infusion. Journal of Neuroimaging, 2020, 30, 146-149.	2.0	6
44	Continuous Local Intra-Arterial Nimodipine for the Treatment of Cerebral Vasospasm. Journal of Neurological Surgery Reports, 2015, 76, e75-e78.	0.6	5
45	Cerebrovascular reactivity after treatment of unruptured intracranial aneurysms — A transcranial Doppler sonography and acetazolamide study. Journal of the Neurological Sciences, 2016, 363, 97-103.	0.6	5
46	A score for paroxysmal atrial fibrillation in acute ischemic stroke. International Journal of Stroke, 2018, 13, 496-502.	5.9	5
47	A Family History of Stroke Is Associated with Increased Intima-Media Thickness in Young Ischemic Stroke - The Norwegian Stroke in the Young Study (NOR-SYS). PLoS ONE, 2016, 11, e0159811.	2.5	5
48	Prevalence of atherosclerosis and association with 5-year outcome: The Norwegian Stroke in the Young Study. European Stroke Journal, 2021, 6, 374-384.	5.5	5
49	Does a History of Migraine Affect the Rate of Thrombolysis in Young Stroke Patients?. Stroke Research and Treatment, 2013, 2013, 1-5.	0.8	3
50	Effect of microbubble contrast on intracranial blood flow velocity assessed by transcranial Doppler. Journal of Ultrasound, 2014, 17, 21-26.	1.3	3
51	Time patterns in multiple acute cerebral infarcts. International Journal of Stroke, 2017, 12, 969-975.	5.9	3
52	Hospital readmissions after spontaneous intracerebral hemorrhage in Southern Portugal. Clinical Neurology and Neurosurgery, 2018, 169, 144-148.	1.4	3
53	The Impact of Ischaemic Stroke Subtype on 30-day Hospital Readmissions. Stroke Research and Treatment, 2018, 2018, 1-7.	0.8	3
54	Time Course of Cerebrovascular Reactivity in Patients Treated for Unruptured Intracranial Aneurysms: A One-Year Transcranial Doppler and Acetazolamide Follow-Up Study. BioMed Research International, 2018, 2018, 1-9.	1.9	3

#	Article	IF	CITATIONS
55	High risk of early neurological worsening of lacunar infarction. Acta Neurologica Scandinavica, 2019, 139, 143-149.	2.1	3
56	Clinical manifestation of acute cerebral infarcts in multiple arterial territories. Brain and Behavior, 2021, 11, e2296.	2.2	3
57	The Course of Carotid Plaque Vulnerability Assessed by Advanced Neurosonology. Frontiers in Neurology, 2021, 12, 702657.	2.4	3
58	A Dark Side of Subcortical Diffusion-Weighted Lesions?. Stroke, 2014, 45, 2710-2716.	2.0	2
59	Comparing withdrawal and not withdrawal of life-sustaining treatment among patients who died from stroke. Vascular Health and Risk Management, 2015, 11, 507.	2.3	2
60	Predictors of long-term survival after spontaneous intracerebral hemorrhage in southern Portugal: A retrospective study of a community representative population. Journal of the Neurological Sciences, 2018, 394, 122-126.	0.6	2
61	Sex Differences in the Norwegian Tenecteplase Trial (NORâ€TEST). European Journal of Neurology, 2021, ,	3.3	2
62	Clinical Importance of Temporal Bone Features for the Efficacy of Contrast-Enhanced Sonothrombolysis: a Retrospective Analysis of the NOR-SASS Trial. Translational Stroke Research, 2018, 9, 333-339.	4.2	1
63	Vascular risk factors and staging of atherosclerosis in patients and controls: The Norwegian Stroke in the Young Study. European Stroke Journal, 2022, 7, 289-298.	5.5	O